YOLFTbeta
OUTLOOK THERAPEUTICS INC

OUTLOOK THERAPEUTICS INC

OTLK · NASDAQ · Healthcare / Biotechnology

0.413USD-0.03 (-6.16%)

Price History

Full chart

Market Stats

Previous Close0.4401
Open0.4629
Day Range0.4102 – 0.4629
52-Week Range0.1611 – 2.54
Volume3.02M
Market Cap151.21M
P/E (TTM)0.00
Forward P/E2.85
EPS-0.70
Dividend Yield0.00%
Beta0.75
50-Day Avg0.828
200-Day Avg0.7724

About

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Robert Charles Jahr
  • Employees17
  • Headquarters111 S. Wood Avenue, Iselin, NJ, United States, 08830, USA
  • Websitehttps://outlooktherapeutics.com

Leadership

  • Mr. Robert Charles JahrPresident, CEO & Director · b. 1973
  • Mr. Kevin LundquistCFO, Treasurer, Principal Financial Officer & Principal Accounting Officer · b. 1968
  • Mr. Joel PrieveSenior Vice President of Licensing and M&A
  • Dr. Surendra Sharma M.D.Senior Vice President of Medical Affairs
  • Dr. Jennifer M. Kissner Ph.D.Senior Vice President of Clinical Development & Regulatory Affairs
  • Mr. Jedd ComiskeySenior VP - Head of Europe

Financials

Income Statement

Currency: USD2014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Revenue9.05M5.22M2.98M3.81M3.09M8.15M5.85M000170.12K1.41M
Growth (%)--42.34%-42.90%+27.92%-18.99%+163.80%-28.14%-100.00%---+730.89%
Cost of Revenue14.12K38.88K32.76K23.81M18.50M23.80M554.07K262.14K204.69K44.19K113.86K756.33K
Gross Profit9.04M5.18M2.95M3.79M3.07M-15.66M-554.07K-262.14K-204.69K-44.19K-113.86K657.21K
Gross Margin99.84%99.26%98.89%99.36%99.39%-192.23%-9.47%----66.93%46.49%
Operating Expense21.43M51.74M54.29M39.67M32.71M20.64M34.42M51.46M62.87M53.08M71.59M67.72M
Operating Income-12.39M-46.56M-51.35M-35.88M-29.64M-36.30M-34.97M-51.73M-63.07M-53.13M-71.70M-67.06M
Operating Margin-136.91%-892.18%-1723.05%-941.24%-959.97%-445.61%-597.44%----42147.63%-4744.25%
EBITDA-11.51M-44.74M-48.95M-30.03M-26.80M-31.11M-34.42M-51.96M-64.36M-56.40M-72.09M-63.58M
EBITDA Margin-127.21%-857.21%-1642.72%-787.78%-867.71%-381.86%-587.97%----42376.79%-4497.70%
Net Income-13.73M-47.39M-53.30M-38.85M-30.09M-34.52M-35.24M-53.16M-66.05M-58.98M-75.37M-62.42M
Net Income Margin-151.72%-908.09%-1788.66%-1019.12%-974.48%-423.82%-602.02%----44301.05%-4416.22%
R&D14.13M38.88M32.76M23.81M18.50M23.80M26.34M38.96M42.33M26.45M41.76M27.78M
R&D as % of Total Revenue156.06%744.89%1099.43%624.61%599.22%292.23%450.02%---24548.59%1965.33%
Interest Expense901.05K2.30M1.85M5.63M3.89M3.47M1.76M936.13K1.49M2.53M3.16M283.13K
Interest Expense % of Total Revenue9.96%44.01%62.15%147.59%126.00%42.56%30.01%---1855.68%20.03%

Balance Sheet

Currency: USD2014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Assets35.01M11.60M23.71M20.73M22.28M17.13M19.73M22.81M28.53M32.30M28.82M18.58M
Total Liabilities64.26M35.15M28.91M51.46M43.09M27.90M16.91M18.20M19.79M46.74M101.90M50.77M
Total Equity-28.60M-23.55M-5.20M-30.73M-20.81M-10.77M2.83M4.61M8.74M-14.44M-73.08M-32.19M
Cash9.07M2.35M2.35M3.19M1.72M8.02M12.54M14.48M17.40M23.39M14.93M8.08M
Total Debt21.96M17.62M8.73M18.42M21.93M14.95M8.80M11.90M10.96M35.56M29.74M30.19M
Net Debt12.89M12.82M6.38M15.23M20.21M6.93M-3.74M-2.57M-6.44M12.16M14.81M22.11M

Cash Flow

Currency: USD2014-09-302015-09-302016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow-7.02M-27.48M-45.48M-15.51M-33.04M-32.29M-31.79M-54.25M-56.67M-42.97M-68.79M-51.83M
Investing Cash Flow-2.37M-8.80M-1.10M-292.09K-2.78M-437.31K-900.00K-----
Financing Cash Flow11.47M43.00M39.86M16.63M34.35M39.03M37.21M56.19M59.59M48.97M60.33M44.98M
Capital Expenditure2.37M8.80M1.10M292.09K2.78M437.31K300203
Free Cash Flow-9.39M-36.28M-46.58M-15.80M-35.82M-32.73M-31.79M-54.25M-56.67M-42.97M-68.79M-51.83M
Dividends Paid8.71M10.88M-16.98B1.89T624.99B166.13B-----
FCF to OCF133.71%132.04%102.41%101.88%108.42%101.35%100.00%100.00%100.00%100.00%100.00%100.00%
Dividend Paid to FCF-92.81%-29.99%--107519.46%-5267757.86%-1909684.26%-522593.63%-----

Earnings

Report DateMay 18, 2016Aug 15, 2016Dec 29, 2016Feb 14, 2017May 15, 2017Aug 14, 2017Dec 29, 2017Feb 14, 2018May 15, 2018Aug 14, 2018Dec 18, 2018Feb 14, 2019May 15, 2019Aug 14, 2019Dec 19, 2019Feb 14, 2020May 15, 2020Aug 14, 2020Dec 23, 2020Feb 16, 2021May 14, 2021Aug 13, 2021Dec 22, 2021Feb 14, 2022May 13, 2022Aug 10, 2022Dec 29, 2022Feb 14, 2023May 15, 2023Aug 14, 2023Dec 22, 2023Feb 14, 2024May 15, 2024Aug 14, 2024Dec 20, 2024Feb 14, 2025May 15, 2025Aug 14, 2025Dec 19, 2025Feb 17, 2026May 15, 2026Aug 14, 2026
EPS Estimate-6.00-120.00-4.48-153.60-152.00-102.40-99.20-1.92-36.80-36.80-0.23-49.60-13.20-7.27-0.31-4.40-2.45-1.90-0.08-1.65-1.80-1.40-1.27-0.06-1.20-1.33-0.07-1.30-1.20-0.87-0.06-1.07-1.07-0.84-0.90-0.62-0.55-0.39-0.06-0.17-0.12-0.09
EPS Actual-2.56-256.00-4.96-131.20-61.25-59.42-35.76-2.48-51.20-32.00-0.32-14.40-19.26-4.80-0.12-5.60-2.60-2.20-0.13-2.20-1.80-1.40-1.60-0.08-1.77-1.56-0.06-1.59-0.52-1.38-0.05-0.78-1.55-0.83-0.940.72-0.40-0.44-0.28-0.22-0.17-0.09
Surprise57.33%-113.33%-10.71%14.58%59.70%41.97%63.95%-29.17%-39.13%13.04%-39.13%70.97%-45.91%33.98%61.29%-27.27%-6.12%-15.79%-62.50%-33.33%0.00%0.00%-25.98%-33.33%-47.50%-17.29%14.29%-22.31%56.67%-58.62%16.67%27.10%-44.86%1.19%-4.10%216.13%27.27%-12.82%-366.67%-29.41%-41.67%0.00%
TimingPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hours-Pre-marketAfter-hoursPre-market

Key Statistics & Ratios

Market Cap151.21M
Enterprise Value168.28M
Trailing P/E0.00
Forward P/E2.85
Price / Sales502.70
Price / Book38.42
EPS-0.70
Book Value-0.056
Revenue (TTM)-1.16M
Gross Profit (TTM)-2.28M
EBITDA-55.53M
Profit Margin0.00%
Operating Margin-124255.27%
Return on Equity-3.65%
Return on Assets-143.17%
Shares Outstanding243.45M
Shares Float196.11M
Beta0.75
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 6 analystsTarget 5.03
  • Strong Buy
    4
  • Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
16.67%
Insiders
12.64%
Retail / Other
70.69%

Top Institutional Holders

  • Armistice Capital, LLC
    4.17M1.72%
  • Perceptive Advisors LLC
    3.14M1.29%
  • Vanguard Capital Management, LLC
    1.97M0.81%
  • Geode Capital Management, LLC
    603.61K0.25%
  • GILPIN WEALTH MANAGEMENT, LLC
    555.00K0.23%
  • BlackRock Inc
    477.47K0.20%
  • Renaissance Technologies Corp
    255.16K0.11%
  • Nine Masts Capital Limited
    232.55K0.10%
  • Vanguard Fiduciary Trust Co
    176.53K0.07%
  • State Street Corp
    163.10K0.07%
  • Susquehanna International Group, LLP
    134.08K0.06%
  • UBS Group AG
    133.07K0.05%
  • SIMPLEX TRADING, LLC
    132.67K0.05%
  • Wealth Management Partners, LLC
    118.17K0.05%
  • Group One Trading, LLC
    113.70K0.05%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    6.93M2.85%
  • Fidelity Extended Market Index
    529.17K0.22%
  • Fidelity Total Market Index
    197.06K0.08%
  • Fidelity Series Total Market Index
    159.58K0.07%
  • Vanguard Balanced Index Inv
    116.49K0.05%

Stock Splits

  • Mar 14, 20241:20
  • Mar 18, 20191:8